• Soligenix's stock climbs as phase 3 lymphoma trial hits goal

    17 days ago - By Fierce Biotech

    A phase 3 trial of Soligenix's cutaneous T-cell lymphoma treatment has squeezed under the bar for statistical significance. The finding sent shares in the nanocap drug developer up almost 50% at points in premarket trading.
    Read more ...